Literature DB >> 9360634

A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues.

J J Yu1, C Mu, K B Lee, A Okamoto, E L Reed, F Bostick-Bruton, K C Mitchell, E Reed.   

Abstract

We studied the DNA sequence of the entire coding region of ERCC1 gene, in five cell lines established from human ovarian cancer (A2780, A2780/CP70, MCAS, OVCAR-3, SK-OV-3), 29 human ovarian cancer tumor tissue specimens, one human T-lymphocyte cell line (H9), and non-malignant human ovary tissue (NHO). Samples were assayed by PCR-SSCP and DNA sequence analyses. A silent mutation at codon 118 (site for restriction endonuclease MaeII) in exon 4 of the gene was detected in MCAS, OVCAR-3 and SK-OV-3 cells, and NHO. This mutation was a C-->T transition, that codes for the same amino acid: asparagine. This transition converts a common codon usage (AAC) to an infrequent codon usage (AAT), whereas frequency of use is reduced two-fold. This base change was associated with a detectable band shift on SSCP analysis. For the 29 ovarian cancer specimens, the same base change was observed in 15 tumor samples and was associated with the same band shift in exon 4. Cells and tumor tissue specimens that did not contain the C-->T transition, did not show the band shift in exon 4. Our data suggest that this alteration at codon 118 within the ERCC1 gene, may exist in platinum-sensitive and platinum-resistant ovarian cancer tissues.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9360634     DOI: 10.1016/s1383-5726(97)00004-6

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  36 in total

Review 1.  Part 1: background, methodology, and clinical adoption of pharmacogenetics.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

2.  Effects of gene polymorphisms on the risk of severe hyponatremia during DCF chemotherapy for patients with esophageal squamous cell carcinoma.

Authors:  Yasuhiro Arakawa; Yoshihiro Shirai; Kazumi Hayashi; Yujiro Tanaka; Akira Matsumoto; Katsunori Nishikawa; Shingo Yano
Journal:  Oncol Lett       Date:  2018-07-31       Impact factor: 2.967

3.  Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1.

Authors:  Rui Gao; Douglas K Price; Tristan Sissung; Eddie Reed; William D Figg
Journal:  Mol Cancer Ther       Date:  2008-05       Impact factor: 6.261

4.  Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia.

Authors:  Jee Hyun Kong; Yeung-Chul Mun; Seonwoo Kim; Hang Seok Choi; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Joon Ho Moon; Sang Kyun Sohn; Sung-Hyun Kim; Chul Won Jung; Dong Hwan Dennis Kim
Journal:  Int J Hematol       Date:  2012-07-21       Impact factor: 2.490

5.  Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.

Authors:  Jennifer M Rubatt; Kathleen M Darcy; Chunqiao Tian; Franco Muggia; Rajiv Dhir; Deborah K Armstrong; Michael A Bookman; Laura J Niedernhofer; Julie Deloia; Michael Birrer; Thomas Carl Krivak
Journal:  Gynecol Oncol       Date:  2012-01-16       Impact factor: 5.482

6.  Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.

Authors:  Julie A Deloia; Nikhil R Bhagwat; Kathleen M Darcy; Mary Strange; Chunquio Tian; Kevin Nuttall; Thomas C Krivak; Laura J Niedernhofer
Journal:  Gynecol Oncol       Date:  2012-05-16       Impact factor: 5.482

7.  Role of DNA repair gene polymorphisms in the efficiency of platinum-based adjuvant chemotherapy for non-small cell lung cancer.

Authors:  Juliette Mathiaux; Valérie Le Morvan; Marina Pulido; Jacques Jougon; Hugues Bégueret; Jacques Robert
Journal:  Mol Diagn Ther       Date:  2011-06-01       Impact factor: 4.074

Review 8.  Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis.

Authors:  Shu-zhen Wei; Ping Zhan; Mei-qi Shi; Yi Shi; Qian Qian; Li-ke Yu; Yong Song
Journal:  Med Oncol       Date:  2010-02-09       Impact factor: 3.064

Review 9.  Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-06-09

10.  Single nucleotide polymorphisms in DNA repair genes and risk of cervical cancer: A case-control study.

Authors:  Lihua Zhang; Zhenchao Ruan; Qingya Hong; Xiangzhen Gong; Zhengguang Hu; Yan Huang; Aidi Xu
Journal:  Oncol Lett       Date:  2011-10-26       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.